THE USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF EBOLA VIRUS DISEASE | Zendy

Т. Е. Сизикова | Zendy; G. V. Borisevich | Zendy; Dmitry V. Shcheblyakov | Zendy; Daria A. Burmistrova | Zendy; В. Н. Лебедев | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

THE USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF EBOLA VIRUS DISEASE

Author(s) -

Т. Е. Сизикова,

G. V. Borisevich,

Dmitry V. Shcheblyakov,

Daria A. Burmistrova,

В. Н. Лебедев

Publication year - 2018

Publication title -

problems of virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.151

H-Index - 15

eISSN - 2411-2097

pISSN - 0507-4088

DOI - 10.18821/0507-4088-2018-63-6-245-249

Subject(s) - ebola virus , monoclonal antibody , virology , ebolavirus , biopharmaceutical , antibody , virus , cytotoxicity , pathogen , biology , immunology , in vitro , biochemistry , genetics

Some drugs candidates for treatment of Ebola virus disease (EVD), have been studied, monoclonal antibody (mAb) cocktails have shown great potential as EVD therapeutics. The advantages of mAb therapy include low toxicity, high specificity and versatility, with the range of biological effects being dependent upon the Fc region. Functions of mAbs include pathogen opsonisation, complement activation, antibody-dependent cell cytotoxicity and virus neutralization characteristics. The most known mAb cocktail, used as therapeutic, is ZMapр, manufactured by «Leaf Biopharmaceutical» from 2004. The elaborated mAb cocktails, structures and properties s of mAbs, the protective characteristics of mAbs and development of new pan-ebolavirus mAbs are reviewed in this article.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research